Abstract:Merkel cell carcinoma (MCC) is a highly malignant skin cancer characterized by early metastases and poor survival. Although MCC is a rare malignancy, its incidence is rapidly increasing in the U.S. and Europe. The discovery of the Merkel cell polyomavirus (MCPyV) has enormously impacted our understanding of its etiopathogenesis and biology. MCCs are characterized by trilinear differentiation, comprising the expression of neuroendocrine, epithelial and B-lymphoid lineage markers. To date, it is generally accept… Show more
“…Initially, the favoured theory was that MCC originates from Merkel cells, which was followed by the hypothesis that a Merkel cell precursor, for example epidermal or dermal stem cells, is the possible cell of origin of MCC 34 . Later, the hypothesis that MCC derives from pro-B cells or pre-B cells was suggested 33,143 , based on the observation that early B cell antigens are expressed in MCC. However, to date, expression of the MCPyV T antigens has not been able to transform any of these cells in vitro .…”
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics. MCC presents with a solitary cutaneous or subcutaneous nodule, most frequently in sun-exposed areas. In fact, UV exposure is probably involved in both viral-mediated and non-viral-mediated carcinogenesis, by contributing to immunosuppression or DNA damage, respectively. Confirmation of diagnosis relies on analyses of histological features and immunological marker expression profiles of the lesion. At primary diagnosis, loco-regional metastases are already present in ~30% of patients. Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease. Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.
“…Initially, the favoured theory was that MCC originates from Merkel cells, which was followed by the hypothesis that a Merkel cell precursor, for example epidermal or dermal stem cells, is the possible cell of origin of MCC 34 . Later, the hypothesis that MCC derives from pro-B cells or pre-B cells was suggested 33,143 , based on the observation that early B cell antigens are expressed in MCC. However, to date, expression of the MCPyV T antigens has not been able to transform any of these cells in vitro .…”
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations. Notably, in the Northern hemisphere, the majority of MCC cases are of viral aetiology; by contrast, in areas with high UV exposure, UV-mediated carcinogenesis is predominant. The two aetiologies share similar clinical, histopathological and prognostic characteristics. MCC presents with a solitary cutaneous or subcutaneous nodule, most frequently in sun-exposed areas. In fact, UV exposure is probably involved in both viral-mediated and non-viral-mediated carcinogenesis, by contributing to immunosuppression or DNA damage, respectively. Confirmation of diagnosis relies on analyses of histological features and immunological marker expression profiles of the lesion. At primary diagnosis, loco-regional metastases are already present in ~30% of patients. Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease. Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.
“…Evidence from animal models suggests that epidermal/dermal stem cells might be the cellular origin of MCC. The recently formulated hypothesis of MCC originating from pro/pre‐B or pre‐B cells is supported by cell morphology, the consistent expression of early B‐cell lineage markers and the finding of clonal immunoglobulin chain rearrangement in MCC cells . Murakami et al .…”
mentioning
confidence: 93%
“…During the past decade, evidence has been accumulating that Merkel cells, which are located at the epidermal–dermal junction, are possibly not the origin of Merkel cell carcinoma (MCC), a relatively rare but highly aggressive skin tumour . In 2013, Zur Hausen et al .…”
mentioning
confidence: 99%
“…They found that one MCC had monoclonal immunoglobulin heavy chain (IgH) and immunoglobulin kappa light chain (IgK) rearrangement, while two other MCCs had IgK rearrangement . As coexpression of TdT and PAX5 is normally restricted to pro/pre‐ and pre‐B cells, the authors suggested that the cells of origin of MCC are pro/pre‐B or pre‐B cells rather than postmitotic Merkel cells . We aimed to assess the frequency of IgH rearrangement in primary MCC.…”
mentioning
confidence: 99%
“…It is widely accepted that the previous hypothesis of MCC originating from Merkel cells is probably incorrect because of the postmitotic character, absence of MCPyV association and different protein expression patterns in Merkel cells compared with MCC . Evidence from animal models suggests that epidermal/dermal stem cells might be the cellular origin of MCC.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.